These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18479922)

  • 21. Aromatase inhibitors: potential reproductive implications.
    Bedaiwy MA; Mousa NA; Casper RF
    J Minim Invasive Gynecol; 2009; 16(5):533-9. PubMed ID: 19608462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Aromatase inhibitors for metastasing breast cancer in postmenopausal women. A survey of a Cochrane review].
    Aziz M; Skougaard K; Kamby C; Nielsen DL
    Ugeskr Laeger; 2008 Jun; 170(25):2248-52. PubMed ID: 18565316
    [No Abstract]   [Full Text] [Related]  

  • 23. Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy.
    Mousa NA; Crystal P; Wolfman WL; Bedaiwy MA; Casper RF
    Menopause; 2008; 15(5):875-84. PubMed ID: 18480735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
    Wardley AM
    Adv Ther; 2008 Dec; 25(12):1257-75. PubMed ID: 19096768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.
    Dorfman CS; Arthur SS; Kimmick GG; Westbrook KW; Marcom PK; Corbett C; Edmond SN; Shelby RA
    Menopause; 2019 Aug; 26(8):823-832. PubMed ID: 30994574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acceptance of adjuvant therapy and quality of life issues.
    Fallowfield L
    Breast; 2005 Dec; 14(6):612-6. PubMed ID: 16169727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study.
    Oh B; Kimble B; Costa DS; Davis E; McLean A; Orme K; Beith J
    Acupunct Med; 2013 Sep; 31(3):264-71. PubMed ID: 23722951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing the risk of distant metastases: a better end point in adjuvant aromatase inhibitor breast cancer trials?
    Tang SC
    Cancer Invest; 2008 Jun; 26(5):481-90. PubMed ID: 18568770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE; Body JJ; Gralow JR; Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aromatase inhibitors in breast cancer.
    Hiscox S; Davies EL; Barrett-Lee P
    Maturitas; 2009 Aug; 63(4):275-9. PubMed ID: 19577386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testosterone therapy for sexual dysfunction in postmenopausal women.
    Hubayter Z; Simon JA
    Climacteric; 2008 Jun; 11(3):181-91. PubMed ID: 18568783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
    Dunn BK; Ryan A
    Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential adverse effects of aromatase inhibitors on wound healing: in vitro and in vivo evidence.
    Howgate DJ; Gamie Z; Panteliadis P; Bhalla A; Mantalaris A; Tsiridis E
    Expert Opin Drug Saf; 2009 Sep; 8(5):523-35. PubMed ID: 19645634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review.
    Lemieux J; Maunsell E; Provencher L
    Psychooncology; 2008 Apr; 17(4):317-28. PubMed ID: 17721909
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aromatase inhibitors in the management of early breast cancer: the TEAM trial.
    Markopoulos C
    Eur J Surg Oncol; 2009 Mar; 35(3):333. PubMed ID: 18455358
    [No Abstract]   [Full Text] [Related]  

  • 37. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Are all aromatase inhibitors alike?
    Blackwell KL
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():35-43. PubMed ID: 19101793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
    Barginear M; Clotfelter A; Poznak CV
    Clin Breast Cancer; 2009 May; 9(2):72-6. PubMed ID: 19433386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.